{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:49Z","timestamp":1792786009023,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016749","name":"Center for Equine Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016749","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State of California satellite wagering fund","id":[{"id":"https:\/\/ror.org\/030sa3819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) can be used to manage insulin dysregulation (ID). Their effect on corticosteroid-induced ID is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Evaluate effects of ertugliflozin on serum insulin and glucose concentrations in horses receiving dexamethasone (DEX). We hypothesized that DEX would induce ID and ertugliflozin coadministration would mitigate that effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seven healthy horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized crossover design; horses received DEX (0.06\u00a0mg\/kg IV q48h; DEX)or ertugliflozin (0.05\u00a0mg\/kg PO q24h) plus DEX (SGLT-2i group) for seven days. Oral sugar (OST) and insulin tolerance (ITT) tests were performed before and after treatment. Insulin and glucose concentrations were measured during treatment. Data were analyzed using mixed-effects linear models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean daily insulin concentrations were lower in the SGLT-2i compared with the DEX group (P\u00a0&amp;lt;\u00a0.001), with a block effect\u2014mean insulin (95% CI) \u03bcIU\/mL: Block 1 DEX 50.6 (42.1-59.1) and SGLT-2i 35.9 (28.1-43.7); Block 2 DEX 34.5 (27.8-41.3) and SGLT-2i 18.9 (16.5-21.4). Glucose was lower in the SGLT-2i group on days 3 and 5 (P\u00a0&amp;lt;\u00a0.001)\u2014mean glucose (95% CI) mg\/dL: Day 3 DEX 117.3 (110.4-124.3) and SGLT-2i 101.0 (95.7-106.4); Day 5 DEX 116.6 (107.9-125.3) and SGLT-2i 101.0 (95.5-106.4). Post-treatment OST insulinT60 was higher in both groups (P\u00a0=\u00a0.01). Glucose concentrations decreased less during the ITT post-treatment in the SGLT-2i group compared with DEX (P\u00a0&amp;lt;\u00a0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Ertugliflozin lowered mean daily serum insulin concentrations in horses receiving DEX. Dynamic tests after drug discontinuation did not indicate ID improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag204","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:27:03Z","timestamp":1790803623000},"source":"Crossref","is-referenced-by-count":0,"title":["The effect of ertugliflozin on serum insulin and glucose in healthy horses receiving dexamethasone"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8143-7786","authenticated-orcid":false,"given":"Florence","family":"Dupuis-Dowd","sequence":"first","affiliation":[{"name":"Veterinary Medical Teaching Hospital, University of California, Davis, School of Veterinary Medicine, Davis, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H","family":"Kass","sequence":"additional","affiliation":[{"name":"Department of Population Health and Reproduction, University of California, Davis, School of Veterinary Medicine, Davis, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-6200","authenticated-orcid":false,"given":"Emily H","family":"Berryhill","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, University of California, Davis, School of Veterinary Medicine, Davis, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093017265765900_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020623","article-title":"Molecular mechanisms of glucocorticoid-induced insulin resistance","volume":"22","author":"Beaupere","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026093017265765900_ref2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2460\/ajvr.68.7.753","article-title":"Effects of dexamethasone on glucose dynamics and insulin sensitivity in healthy horses","volume":"68","author":"Tiley","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026093017265765900_ref3","first-page":"617","article-title":"Diagnostic evaluation of insulin and glucose dynamics in light-breed horses receiving dexamethasone","volume":"63","author":"Timko","year":"2022","journal-title":"Can Vet J"},{"key":"2026093017265765900_ref4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2746\/042516407X166792","article-title":"The corticosteroid laminitis story: 1. Duty of care","volume":"39","author":"Dutton","year":"2007","journal-title":"Equine Vet J"},{"key":"2026093017265765900_ref5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.2042-3306.1973.tb03191.x","article-title":"Lung function tests in obstructive pulmonary disease in horses","volume":"5","author":"Muylle","year":"1973","journal-title":"Equine Vet J"},{"key":"2026093017265765900_ref6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/vr.105378","article-title":"Prevalence of and risk factors for acute laminitis in horses treated with corticosteroids","volume":"185","author":"Potter","year":"2019","journal-title":"Vet Rec"},{"key":"2026093017265765900_ref7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4142\/jvs.2004.5.3.271","article-title":"Glucocorticoid-induced laminitis with hepatopathy in a thoroughbred filly","volume":"5","author":"Ryu","year":"2004","journal-title":"J Vet Sci"},{"key":"2026093017265765900_ref8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.tvjl.2007.07.003","article-title":"Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies","volume":"174","author":"Asplin","year":"2007","journal-title":"Vet J"},{"key":"2026093017265765900_ref9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2746\/042516409X475779","article-title":"Equine laminitis: induced by 48 h hyperinsulinaemia in standardbred horses","volume":"42","author":"Laat","year":"2010","journal-title":"Equine Vet J"},{"key":"2026093017265765900_ref10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.tvjl.2012.07.003","article-title":"Histological and morphometric lesions in the pre-clinical, developmental phase of insulin-induced laminitis in standardbred horses","volume":"195","author":"Laat","year":"2013","journal-title":"Vet J"},{"key":"2026093017265765900_ref11","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jvim.15138","article-title":"Insulin dysregulation in horses with systemic inflammatory response syndrome","volume":"32","author":"Bertin","year":"2018","journal-title":"J Vet Intern Med"},{"key":"2026093017265765900_ref12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet."},{"key":"2026093017265765900_ref13","doi-asserted-by":"publisher","first-page":"e0203655","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PloS One"},{"key":"2026093017265765900_ref14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12917-019-1811-2","article-title":"The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies","volume":"15","author":"Meier","year":"2019","journal-title":"BMC Vet Res"},{"key":"2026093017265765900_ref15","doi-asserted-by":"publisher","first-page":"e70256","DOI":"10.1111\/jvim.70256","article-title":"Effects of the sodium-glucose cotransporter-2 inhibitor velagliflozin on insulin concentrations in horses with insulin dysregulation","volume":"39","author":"Thane","year":"2025","journal-title":"J Vet Intern Med"},{"key":"2026093017265765900_ref16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Vet J"},{"key":"2026093017265765900_ref17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/eve.13738","article-title":"Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series","volume":"35","author":"Sundra","year":"2023","journal-title":"Equine Vet Educ"},{"key":"2026093017265765900_ref18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jvp.13470","article-title":"Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses","volume":"48","author":"Menzies-Gow","year":"2025","journal-title":"J Vet Pharmacol Ther"},{"key":"2026093017265765900_ref19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13300-019-0566-x","article-title":"Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis","volume":"10","author":"McNeill","year":"2019","journal-title":"Diabetes Ther"},{"key":"2026093017265765900_ref20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/evj.12826","article-title":"Effect of varying the dose of corn syrup on insulin and glucose response to the oral sugar test","volume":"50","author":"Jocelyn","year":"2018","journal-title":"Equine Vet J"},{"key":"2026093017265765900_ref21","article-title":"Recommendations for the diagnosis and management of equine metabolic syndrome (EMS) and insulin dysregulation","author":"Bertin","year":"2024:9","journal-title":"Published"},{"key":"2026093017265765900_ref22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2885.1996.tb00011.x","article-title":"The pharmacokinetics of dexamethasone in the thoroughbred racehorse","volume":"19","author":"Cunningham","year":"1996","journal-title":"J Vet Pharmacol Ther"},{"key":"2026093017265765900_ref23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/oby.2003.90","article-title":"Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers","volume":"11","author":"Nicod","year":"2003","journal-title":"Obesity Res"},{"key":"2026093017265765900_ref24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/01.mco.0000172588.47811.63","article-title":"The regulation of glucose effectiveness: how glucose modulates its own production","volume":"8","author":"Tonelli","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2026093017265765900_ref25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12917-025-05173-1","article-title":"Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue","volume":"22","author":"Anger-H\u00e5\u00e5l","year":"2025","journal-title":"BMC Vet Res"},{"key":"2026093017265765900_ref26","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/jvim.16906","article-title":"Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: a randomized, placebo-controlled, double-blind, study","volume":"37","author":"Lind\u00e5se","year":"2023","journal-title":"J Vet Intern Med"},{"key":"2026093017265765900_ref27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2337\/db19-0770","article-title":"Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors","volume":"69","author":"Alatrach","year":"2020","journal-title":"Diabetes."},{"key":"2026093017265765900_ref28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026093017265765900_ref29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2460\/ajvr.71.7.831","article-title":"Pharmacokinetics and pharmacodynamics of dexamethasone after oral administration in apparently healthy horses","volume":"71","author":"Grady","year":"2010","journal-title":"Am J Vet Res"},{"key":"2026093017265765900_ref30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab"},{"key":"2026093017265765900_ref31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/clinem\/dgad438","article-title":"Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin\/exenatide therapy in type 2 diabetes","volume":"109","author":"Cersosimo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026093017265765900_ref32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/cea.12505","article-title":"Effects of short-term oral corticosteroid intake on dietary intake, body weight and body composition in adults with asthma: a randomized controlled trial","volume":"45","author":"Berthon","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"2026093017265765900_ref33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5455\/OVJ.2023.v13.i3.14","article-title":"Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors","volume":"13","author":"Kellon","year":"2023","journal-title":"Open Vet J"},{"key":"2026093017265765900_ref34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026093017265765900_ref35","doi-asserted-by":"publisher","first-page":"106894","DOI":"10.1016\/j.domaniend.2024.106894","article-title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series","volume":"90","author":"Sundra","year":"2025","journal-title":"Domest Anim Endocrinol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/5\/aalag204\/71532369\/aalag204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/5\/aalag204\/71532369\/aalag204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:27:04Z","timestamp":1790803624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag204\/8855726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag204","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"aalag204"}}